drugset / Trial / NCT01980732

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

NCT01980732 ↗

Expanded access No longer available Andrei Iagaru

Summary

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATATE Diagnostic / imaging agent — —